comprehensive -WSS

comprehensive

author：focus 2025-09-28 01:24:08 - browse：9633

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Biden report: The neurospychology of memory and aging

Wikipedia

WSS

HIV drugs protect against transmission, even in unprotected sex

Gilead might be held responsible for not developing a drug

Industry veterans launch new biotech VC with $310M

Woman returns to dialysis after doctors remove transplanted pig kidney

How digital tools helped lower hypertension in marginalized patients

See how much Covid

entertainment

comprehensive

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

PhRMA lawsuit over Medicare drug price negotiation tossed

What does generative AI mean for health care? We asked experts

HIV drugs protect against transmission, even in unprotected sex

Alkermes shareholders re

BMI, flaws aside, is found to be useful estimate of body fat in youth

The cancer drug shortage isn’t new — and neither are the solutions

Change Healthcare can notify patients about the breach, HHS says

Medicare details structure of new drug price negotiation program

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

hotspot

With trial win, GSK could get blood cancer drug back on market

ASCO: Palliative care found as helpful given virtually as in person

Biogen Alzheimer’s drug launch off to slow start

For Medicare Advantage, Democrats want stronger protections around AI

Biogen Alzheimer’s drug launch off to slow start

Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

hotspot

Wikipedia

focus